Clinical trials: Antipsychotics
Imaging of the Brain and Antipsychotics, Neuronal Network Changes
Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers
To detect the effect of second-generation antipsychotic drug on the neural activity.
- Trial name
- NCT01931059
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Pharmacogenetics, Healthy
Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers
The purpose of this study is to determine in healthy volunteers treated with typical or atypical antipsychotics -AP-, the relationship between genetic polymorphisms in cytochrome genes CYP2D6 (*3, *4, *5, *6 and Nxn) and CYP3A5…
- Trial name
- APSEP (NCT01259973)
- Testing
- Risperidone, Haloperidol
- Where
- 2 sites in Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Schizophrenia, Obesity
Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia
Background: Although second-generation antipsychotic medications have fewer serious side effects and complications than first-generation ones, they are strongly associated with weight gain for reasons that are as yet unknown.
- Trial name
- NCT01222793
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Conduct Disorder, fMRI
Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders
Background: Some children and teenagers have conditions known as conduct disorders. They often have long-term chronic behavior problems, such as defiant behavior or violence.
- Trial name
- NCT01867398
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone
The purposes of this study are to estimate the relationship of D2-receptor occupancy to plasma concentration and to assess the safety of OROS paliperidone.
- Trial name
- NCT00796432
- Testing
- OROS paliperidone
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville
The purpose of this study is to establish bioequivalence of paliperidone ER tablets manufactured at Gurabo as compared to paliperidone ER tablets manufactured at Vacaville, administered as a single dose of 12 mg under fasted…
- Trial name
- NCT00790777
- Testing
- Paliperidone ER
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psychotic Disorder, SCHIZOPHRENIA 1 (Disorder)
Ultrasound Assessment of Gluteal Muscle in Patients Receiving Depot Antipsychotics and Healthy Volunteers
This observational study will use ultrasound to assess the gluteal musculature in patients receiving depot antipsychotic medication and in healthy volunteers.
- Conditions
- Psychotic Disorder, SCHIZOPHRENIA 1 (Disorder), Intramuscular Injection
- Trial name
- ULPSYK (NCT07815587)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- St. Olavs Hospital
Schizophrenia
Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia
The aim of the present study is to detect changes in the dopamine system in the brain of patients with schizophrenia, especially when pretreated with antipsychotic medication.
- Trial name
- NCT03911726
- Testing
- Single PET/MR-measurement
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Pregnant Women, Psychotropic Drugs
National Pregnancy Registry for Psychiatric Medications
The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many…
- Trial name
- NCT01246765
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism
The study is aimed to assess the severities of hyperprolactinemia caused by antipsychotic drugs and the effects of the duration of hyperprolactinemia on bone metabolism in schizophrenia patients.
- Trial name
- NCT03675750
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Adolescent Depression
Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy
We hypothesize that antipsychotic induced hyperprolactinemia can decrease bone mineral accrual and decrease bone mineral content (BMC) in adolescents on antipsychotic therapy. Specifics Aims 1.
- Trial name
- NCT00399776
- Testing
- Bone Density Test
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Creighton University
Bipolar Disorders, Metabolic Complication
Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders
The primary goal of this study is to investigate metabolic changes and maintaining efficacy in stabilized patients with bipolar disorders who have pharmacologically induced weight gain.
- Trial name
- NCT00845988
- Testing
- aripiprazole
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia or Schizoaffective Disorder
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body in healthy participants and subjects with schizophrenia and whether it causes any side effects.
- Trial name
- MAD (NCT02504476)
- Testing
- AMG 581, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Amgen
Death, Sudden, Cardiac, Arrythmia
Monitoring of Arrhythmias in Patients Treated With Antipsychotics
Antipsychotics may be associated to life-threatening arrhythmias and sudden cardiac death. This is the fist study to estimated the arrhythmic burden using long-term monitoring by implantable loop recorder in patients treated with…
- Conditions
- Death, Sudden, Cardiac, Arrythmia, Antipsychotics and Neuroleptics Toxicity
- Trial name
- MAPP (NCT04575103)
- Testing
- Antipsychotic
- Where
- 18 sites in Denmark
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Herlev and Gentofte Hospital
Schizophrenia, Schizoaffective Disorder
The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy
Background: Among individuals with schizophrenia, there is an increased prevalence of obesity, dyslipidemia ,diabetes mellitus and related conditions such as cardiovascular disease.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01215383
- Where
- Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ziv Hospital
Borderline Personality Disorder
Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder
Objective: The objective of this study is to quantitatively examine the efficacy of Seroquel (active ingredient quetiapine fumarate) in subjects with Borderline Personality Disorder (BPD).
- Trial name
- NCT00122070
- Testing
- Quetiapine Fumarate
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Medicine and Dentistry of New Jersey
Schizophrenia
A Bioequivalence Study of 15 mg ER OROS Paliperidone
The purpose of this study is to evaluate the bioequivalence between the Phase 3 and the to-be-marketed formulations of extended release (ER) OROS paliperidone and to evaluate the effect of food on the highest to be marketed…
- Trial name
- NCT00892489
- Testing
- ER OROS Paliperidone
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cardio Vascular Disease, Metabolic Syndrome (MetS)
Norwegian Mental Illness Heart Health Study
Norwegian patients with severe mental illnesses (SMI), such as schizophrenia spectrum or bipolar disorder, lose on average 10 years of life compared to mentally healthy individuals. Much of this gap is due to heart disease.
- Conditions
- Cardio Vascular Disease, Metabolic Syndrome (MetS), Severe Mental Disorder, Schizophrenia and Schizophrenia Spectrum Psychosis
- Trial name
- NORMI-Heart (NCT07085923)
- Testing
- Lifestyle Intervention
- Where
- Norway
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Madeleine Elisabeth Angelsen
Schizophrenia
Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia.
- Trial name
- NCT00333177
- Testing
- Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris)
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Neuropsychiatric Symptom
Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases
The goal of this observational cohort study is to investigate the role of immune system in neuropsychiatric symptoms (NPS) and to identify immunological biomarkers that may improve the diagnosis, prognosis, and future treatment…
- Trial name
- DIAMOND (NCT07791212)
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- King's College London